0001104659-23-029720.txt : 20230307
0001104659-23-029720.hdr.sgml : 20230307
20230307191712
ACCESSION NUMBER: 0001104659-23-029720
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230306
FILED AS OF DATE: 20230307
DATE AS OF CHANGE: 20230307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Derby Michael
CENTRAL INDEX KEY: 0001809613
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41475
FILM NUMBER: 23714407
MAIL ADDRESS:
STREET 1: 303 SOUTH BROADWAY
STREET 2: SUITE 125
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PaxMedica, Inc.
CENTRAL INDEX KEY: 0001811623
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 303 SOUTH BROADWAY, SUITE 125
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 914-987-2876
MAIL ADDRESS:
STREET 1: 303 SOUTH BROADWAY, SUITE 125
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
4
1
tm238845-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-03-06
0
0001811623
PaxMedica, Inc.
PXMD
0001809613
Derby Michael
C/O PAXMEDICA, INC.
303 SOUTH BROADWAY, SUITE 125
TARRYTOWN
NY
10591
1
1
1
0
Executive Chairman
Common Stock
2023-03-06
4
S
0
13828
1.72
D
341707
D
Common Stock
2023-03-07
4
S
0
15134
1.55
D
326573
D
Common Stock
7336745
I
TardiMed Sciences, LLC
The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person.
This sale price represents the weighted average sale price of the shares sold ranging from $1.90 to $1.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
This sale price represents the weighted average sale price of the shares sold ranging from $1.67 to $1.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
/s/ Stephen D. Sheldon, Jr. Attorney-in-Fact
2023-03-07